Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy

Acta Oncologica

Volumn 47, Issue 7, 2008, Pages 1257-1264

  Røe, Kathrine ^a   Muren, Ludvig P ^b   Rørvik, Jarle ^c,d   Olsen, Dag R ^a   Dahl, Olav ^c,d   Bakke, August ^d   Malinen, Eirik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 51049087282     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802244174     Document Type: Article

References (23)

1. Loncaster JA, Carrington BM, Sykes JR, Jones AP, Todd SM, Cooper R, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54:759-67.
2. Gong QY, Brunt JN, Romaniuk CS, Oakley JP, Tan LT, Roberts N, et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: Early prediction of tumour regression rate. Br J Radiol 1999;72:1177-84.
3. Horsman MR, Overgaard J. Basic clinical radiobiology. 2nd ed. London: Arnold; 1997. p 132-141.
4. Bentzen SM. Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 2005;77:227-30.
5. Malinen E, Søvik Å, Hristov D, Bruland ØS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006;51:4903-21.
6. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 2000;48:593-9.
7. Wang JZ, Li XA. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 2005;61:220-7.
8. Tomé WA, Fowler JF. On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours. Phys Med Biol 2003;48:N261-N268.
9. Søvik Å, Malinen E, Skogmo HK, Bentzen SM, Bruland ØS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007;68:1496-504.
10. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus A, et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 2001;14:750-6.
11. UICC (International Union Against Cancer), Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. TNM-Atlas. 4th ed. Berlin: Springer Verlag; 1997. p 309-314.
12. Haider MA, Sitartchouk I, Roberts TPL, Fyles A, Hashmi AT, Milosevic M. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer. J Magn Reson Imaging 2007;25:153-9.
13. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-9.
14. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
15. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
16. Walker-Samuel S, Leach MO, Collins DJ. Evaluation of response to treatment using DCE-MRI: The relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006;51:3593-602.
17. Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, Lin PC, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: A reference region model. Magn Reson Imaging 2005;23:519-29.
18. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007;8:63-74.
19. Yamashita Y, Baba T, Baba Y, Nishimura R, Ikeda S, Takahashi M, et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: Pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000;216:803-9.
20. Robinson P, Collins CD, Ryder WDJ, Carrington BM, Hutchinson CE, Bell D, et al. Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy. Clin Radiol 2000;55:301-6.
21. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42.
22. Muren LP, Smaaland R, Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol 2003;69:291-304.
23. Redpath AT, Muren LP. CT-guided intensity-modulated radiotherapy for bladder cancer: Isocentre shifts, margins and their impact on target dose. Radiother Oncol 2006;81:276-83.